Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Tumor Blood Testing Market Value Analysis: What Growth Lies Ahead Over The Forecast Period?
The tumor blood testing market has experienced substantial expansion in recent times. This market is projected to expand from $5.98 billion in 2025 to $6.78 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 13.3%. Historically, this growth has been driven by several factors, including an increase in cancer prevalence, the constraints of tissue biopsy, breakthroughs in genomic testing, investment in oncology research funding, and the rising demand for non-invasive diagnostic methods.
The tumor blood testing market is anticipated to experience substantial expansion in the coming years. This market is projected to reach $11.13 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 13.2%. This projected growth is driven by factors such as the implementation of early cancer screening initiatives, advancements in AI-enabled genomic analysis, the rise of personalized medicine, broader use of companion diagnostics, and increased adoption in clinical trials. Key developments anticipated during this period encompass the widespread adoption of liquid biopsies, advancements in multi-cancer early detection, enhanced minimal residual disease monitoring, tailored oncology testing, and the identification of high-sensitivity biomarkers.
Get A Free Sample Report With In-Depth Market Insights:
Tumor Blood Testing Market Growth Factors Behind Sustained Expansion
The rising incidence of cancer is anticipated to propel the expansion of the tumor blood testing market over the next few years. An aging global demographic and exposure to various risk factors, including inadequate nutrition, tobacco use, and environmental contaminants, are leading to a greater occurrence of cancer, thereby boosting the need for swift diagnostic techniques. This method, known as tumor blood testing, offers a non-invasive way to identify cancer prior to the onset of symptoms through the detection of specific biomarkers present in the bloodstream. Such testing facilitates prompt diagnosis, earlier therapeutic intervention, enhanced patient prognoses, and continuous observation of disease advancement and the efficacy of treatments. To illustrate, in May 2024, data from the National Cancer Institute, a US-based government agency, indicated that by January 2022, approximately 18.1 million cancer survivors resided in the United States, with forecasts suggesting this figure will climb to 26 million by 2040. Consequently, the growing frequency of cancer cases is a primary factor stimulating the expansion of the tumor blood testing market.
Tumor Blood Testing Market Segment Analysis Spotlighting Growth Areas
The tumor blood testing market covered in this report is segmented –
1) By Test Type: Circulating Tumor Cells (CTC) Tests, Circulating Tumor DNA (CtDNA) Tests, Exosome-Based Tests, Other Test Types
2) By Technology: Polymerase Chain Reaction (PCR)-Based Testing, Next-Generation Sequencing, Immunoassays
3) By Cancer Type: Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer, Melanoma
4) By Application: Early Cancer Screening, Therapy Selection, Treatment Monitoring, Recurrence Monitoring
5) By End User: Hospitals, Diagnostic Laboratories, Research Institutes, Other End-Users
Subsegments:
1) By Circulating Tumor Cells Tests: Isolation Of Tumor Cells, Enumeration Of Tumor Cells, Characterization Of Tumor Cells
2) By Circulating Tumor DNA Tests: Mutation Detection Of Tumor DNA, Methylation Analysis Of Tumor DNA, Copy Number Variation Analysis Of Tumor DNA, Fragmentation Analysis Of Tumor DNA
3) By Exosome-Based Tests: Protein Profiling Of Exosomes, RNA Profiling Of Exosomes, Lipid Profiling Of Exosomes, Surface Marker Analysis Of Exosomes
4) By Other Tests: Circulating RNA Tests, Tumor Educated Platelet Tests, Protein Biomarker Panels, Multiomics Blood Tests, Immuno Oncology Biomarker Tests
Tumor Blood Testing Market Industry Trends Fueling Future Revenue Growth
Leading firms within the tumor blood testing market are concentrating on advancing novel technologies, particularly non-invasive liquid biopsy methods, to improve the efficiency of early cancer detection, treatment monitoring, and disease progression assessment. These non-invasive liquid biopsy technologies represent diagnostic tools that identify and evaluate cancer-associated biomarkers present in bodily fluids, offering a safer and more user-friendly option compared to conventional tissue biopsies. An example of this innovation is the launch in February 2024 of the DELFI-Tumor Fraction (DELFI-TF) assay, a blood test designed for cancer monitoring, by US-based biotechnology company Delfi Diagnostics in partnership with UK-based biotechnology company Immunocore Holdings plc. This assay functions by examining cell-free DNA (cfDNA) fragments found in the bloodstream to determine tumor burden and gauge response to treatment. Such a fragmentome-based liquid biopsy presents a non-invasive and economical alternative to established approaches, needing only a small amount of plasma and delivering results within two weeks.
Tumor Blood Testing Market Industry Leaders And Competitive Landscape
Major companies operating in the tumor blood testing market are Bio-Techne Corporation, Roche Holding AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Siemens Healthineers AG, Illumina Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., Natera Inc., Myriad Genetics Inc., Neogenomics Laboratories Inc., Guardant Health Inc., Foundation Medicine Inc., Adaptive Biotechnologies Corporation, Freenome Holdings Inc., Grail Inc., Personal Genome Diagnostics Inc., Exosome Diagnostics Inc., Agena Bioscience Inc., Menarini Silicon Biosystems S.p.A.
View The Full Tumor Blood Testing Market Report:
Tumor Blood Testing Market Regional Analysis And Top Geography
North America was the largest region in the tumor blood testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the tumor blood testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
